Please assess the completion status of the following clinical trial:

Trial Title: Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ages 18 to 64~* Prior history of elevated nighttime blood pressure (BP) ((systolic blood pressure (SBP) \> 115mmHg))~* Taking no more than 2 antihypertensive medications~* African American (self-defined by the participant)~Exclusion Criteria:~* Secondary forms of hypertension~* Presence of other diseases requiring treatment with BP lowering medication~* Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or history of cerebrovascular disease, including stroke and transient ischemic attacks)~* Diabetes mellitus (Type 1 or 2)~* Cancer/malignancy other than nonmelanoma skin cancer~* Primary renal disease~* Serum creatinine \> 1.5 mg/dL in men or \> 1.4 mg/dL in women~* Severe anemia~* Liver enzymes \> 2.5 times upper limits of normal~* Hepatitis B, Hepatitis C, or HIV positive as assessed by questionnaire~* Current treatment with or regular use of calcium channel blocking agents, cyclooxygenase-2 inhibitors (COX2-I), oral contraceptives, estrogen, sildenafil, vardenafil, tadalafil, antidepressants, corticosteroids, or warfarin~* Current use of melatonin or any sleep aids containing melatonin~* Regular consumption (1 or more times per week) of: Vitamin methyl B12, St. Johns Wort, feverfew, black and white mustard seeds, wolf berry seed~* Severe Sleep apnea~* Night work~* Women who are pregnant, breast feeding, attempting conception, or planning to attempt conception over the next 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).